The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients:adaptation of INNOVATE to Sweden

References

• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 Step 4 treatment): INNOVATE. Allergy 2005a;60:309–16
   PubMed Web of Science ®Google Scholar
• Tough SC, Hessel PA, Ruff M, et al. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657–65
   PubMed Web of Science ®Google Scholar
• Turner MO, Noertjojo K, Vedal S, et al. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998;157:1804–9
   PubMed Web of Science ®Google Scholar
• Weber EJ, Silverman RA, Callaham ML, et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. Am J Med 2002;113: 371–8
   PubMed Web of Science ®Google Scholar
• Hartert TV, Speroff T, Togias A, et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002;89:467–73
   PubMed Web of Science ®Google Scholar
• Pollack Jr CV, Pollack ES, Baren JM, et al. A prospective multicenter study of patient factors associated with hospital admission from the emergency department among children with acute asthma. Arch Pediatr Adolesc Med 2002;156: 934–40
   PubMed Web of Science ®Google Scholar
• Sidebotham HJ, Roche WR. Asthma deaths; persistent and preventable mortality. Histopathology 2003;43:105–17
   PubMed Web of Science ®Google Scholar
• Jalaludin BB, Smith MA, Chey T, et al. Risk factors for asthma deaths: a population-based, case-control study. Aust New Zealand J Public Health 1999;23:595–600
   PubMed Web of Science ®Google Scholar
• Lee P, Abisheganaden J, Chee CB, Wang YT. A new asthma severity index: a predictor of near-fatal asthma? Eur Respir J 2001;18:272–8
   PubMed Web of Science ®Google Scholar
• Burr ML, Davies BH, Hoare A, et al. A confidential inquiry into asthma deaths in Wales. Thorax 1999;54:985–9
   PubMed Web of Science ®Google Scholar
• Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998;12: 1322–6
   Google Scholar
• Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723–9
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636–42
   PubMed Web of Science ®Google Scholar
• Turk F, Kay S, Higgins V. The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study. Poster presented at the British Thoracic Society Meeting, 7–9 December 2005; London (UK)
   Google Scholar
• Turk F, Piercy J, Benford M. The human impact of severe persistent allergic asthma: results from a multinational study. Poster presented at the ISPOR 8th Annual European Congress, 6–8 November 2005; Florence(Italy)
   Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184–90
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254–61
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701–8
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709–17
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302–8
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632–8
   PubMed Web of Science ®Google Scholar
• Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:1088–94
   PubMed Web of Science ®Google Scholar
• Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111:278–84
   PubMed Web of Science ®Google Scholar
• Holgate S, Bousquet J, Wenzel S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17:233–40
   PubMed Web of Science ®Google Scholar
• Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111:87–90
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Decided on 24 April 2003 [online]. Available from http://www.lfn.se/upload/English/ENG_lfnar2003-eng.pdf [last accessed 22 February 2006]
   Google Scholar
• Ayre G, Fox H, Chen H, et al. Evaluating response to omalizumab (anti-IgE) in clinical practice. Poster presented at the European Respiratory Society Meeting, 17–21 September 2005; Copenhagen
   Google Scholar
• Humbert M, Fox H, Hedgecock S, et al. Physicians judge addon omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis. Poster presented at European Respiratory Society Meeting, 17–21 September 2005; Copenhagen
   Google Scholar
• Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341–64
   PubMed Web of Science ®Google Scholar
• Lowhagen O, Ekstrom L, Holmberg S, et al. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243–7
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference-based single indices from non-preference-based condition-specific instruments: converting AQLQ into EQ-5D indices. Sheffield (UK): ScHARR, University of Sheffield; 2002
   Google Scholar
• Young TA, Yang Y, Brazier J, Tsuchiya A. Using Rash analysis to aid the construction of preference-based measures from existing quality of life instruments. Poster presented at the Health Economics Study Group Meeting; 29 June–1 July 2005; University of Newcastle upon Tyne, UK
   Google Scholar
• Yang Y, Tsuchiya A, Brazier J, Young TA. Estimating a preference-based single index from the Asthma Quality of Life Questionnaire (AQLQ). Poster presented at the Health Economists’ Study Group Meeting, 5–7 January 2006; London, UK
   Google Scholar
• Price D, Brown RE, Lloyd A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Resp J 2004;13:113
   Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Benefits Board. Price database for reimbursed drugs in Sweden [online]. Available from http://www.lfn.se/LFNTemplates/ProductMedSearch_385.aspx [last accessed 15 September 2005]
   Google Scholar
• Dewilde S, Rapatz G, Turk F. The cost of asthma exacerbations of different severity levels. Value in Health 2005;8:A31
   Google Scholar
• Andersson F, Stahl E, Barnes PJ, et al. Adding formoterol to budesonide in moderate asthma – health economic results from the FACET study. Respir Med 2001;95:505–12
   PubMed Web of Science ®Google Scholar
• Henriksson F. Economic aspects of chronic diseases: multiple sclerosis and diabetes mellitus. Stockholm: Karolinska Institutet; 2001
   Google Scholar
• The Swedish Association of Local Authorities and Regions. Cost per patient database (DRG 096) [online]. Available from http://sas.lf.se/kppprod/index.htm [last accessed 23 February 2006]
   Google Scholar
• Statistics Sweden. Wage statistics [online]. Available from http://www.scb.se/templates/publdb/publikation_2725.asp&plopnr=1525 [last accessed 23 February 2006]
   Google Scholar
• Mattias E. Studies in health economics. Modelling and data analysis of costs and survival: Stockholm School of Economics; 2002
   Google Scholar
• Lundberg L, Johannesson M, Isacson DGL, Borgquist L. Health state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Pub Health 1999;9:211–7
   Web of Science ®Google Scholar
• Persson U, Hjelmgren J. Health services need knowledge of how the public values health. Lakartidningen 2003;100:3436–7
   PubMedGoogle Scholar
• Socialstyrelsen (National Board of Health and Welfare). The Swedish National Board of Health and Welfare’s guidelines for cardiac care 2004: support for decisions in setting priorities [online]. Available from http://www.socialstyrelsen.se/Publicerat/2004/8511/2004–102–2.htm [last accessed 15 November 2005]
   Google Scholar
• Miller AK, Zheng B, Fox H, et al. Significant association between previous and future asthma exacerbations in TENOR. Abstract presented at the American College of Allergy, Asthma and Immunology (ACAAI), 12–17 November 2004; Boston (MA)
   Google Scholar
• Juniper EF, Svensson K, Mork AC, et al. Measuring health-related quality of life in adults during an acute asthma exacerbation. Chest 2004;125:93–7
   PubMed Web of Science ®Google Scholar
• Chipps B, Kim K, Korenblat P, et al. Effect of omalizumab on healthcare utilization in patients with moderate-to-severe allergic asthma. Poster presented at the American Academy of Allergic Asthma and Immunology, 7–12 March 2003; Denver (CO)
   Google Scholar
• Israel E, Cohn JR, Meltzer EO, et al. Omalizumab does not induce thrombocytopenia in the treatment of asthma. Poster presented at the American Academy of Allergic Asthma and Immunology, 7–12 March 2003; Denver (CO)
   Google Scholar
• Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med 2006;100:434–50
   Google Scholar
• Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with Etanercept or Infliximab in southern Sweden. Ann Rheum Dis 2004;63:4–10
   Google Scholar
• Jobanputra P. HTA report: clinical effectiveness and cost effectiveness of new drug treatments for rheumatoid arthritis: Etanercept and Infliximab. 2001
   Google Scholar